N-terminal pro-brain BNP (NT-proBNP) have been extensively studied for their predictive value in patients with heart failure. A systematic review now reveals that BNP is a strong prognostic ...

B-type natriuretic peptide is released by cardiac myocytes in response to wall stretch. There are many hemodynamic effects of BNP which are beneficial in the setting of decompensated congestive ...

An assay measuring N-terminal pro-BNP, or NT-proBNP, is more sensitive to detect heart failure and used in many institutions. The levels of BNP and NT-proBNP are essentially the same in normal ...

The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has ...

Possible Roles for Nesiritide in the Management of Heart Failure Although the majority of heart failure patients are ambulatory, with NYHA functional class I or II symptoms, the bulk of clinical ...

Heart failure affects about 900,000 people in the UK. It happens when the heart becomes damaged, for example after a heart attack, and cannot pump blood around the body properly. B-type natriuretic ...

New research reveals how fluoxetine boosts immune protection and prevents sepsis-related heart and metabolic damage.

The "Global Cardiac Biomarkers Diagnostics Industry, 2024-2029" report has been added to ResearchAndMarkets.com's offering. This research service provides an overview of the global cardiac biomarkers ...